Form 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data
|
|
- Aldous Barber
- 6 years ago
- Views:
Transcription
1 Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Research ID: Event date: - - HCT type: (check all that apply) Autologous Allogeneic, unrelated Allogeneic, related Product type: (check all that apply) Bone marrow PBSC Single cord blood unit Multiple cord blood units Other product Specify: Subsequent Transplant or Cellular Therapy If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has t been completed for the previous transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with consent, prior cellular therapy was t reported to the CIBMTR), begin the form at question one. If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one. Is this the report of a second or subsequent transplant or cellular therapy for the same disease? 1 What was the date of diagsis? What was the disease status? (at diagsis) Chronic phase Accelerated phase Blast phase 3 Specify the chronic phase risk score used (at diagsis) EUTOS Hasford Sokal Other Disease Assessment at Diagsis Questions: 1-17 In the treating provider's opinion, specify the risk score: 4 Specify the EUTOS score: 5 Specify the Hasford score: 6 Specify the Sokal score: 7 Specify other chronic phase score: 8 Specify other chronic phase risk score used: 9 Specify blast phase phetype Lymphoid Myeloid Mixed phetype 10 Specify the criteria used to establish accelerated phase or blast phase World Health Organization (WHO) International Bone Marrow Transplant Registry (IBMTR) Sokal MD Anderson European Leukemia Net Other 11 Specify other criteria: 12 Specify the spleen size: centimeters below left lower costal margin 13 Was extramedullary disease present? Specify site(s) of disease: 14 Central nervous system 15 Granulocytic sarcoma Copyright(c) 2012 National Marrow Dor Program and The Medical College of Wisconsin, Inc. All rights reserved. Page 1 / 10
2 Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data 16 Other site 17 Specify other site: Laboratory Studies at Diagsis Questions: WBC 21 Report findings prior to any first treatment for CML: 19 x 109/L (x 103/mm3) 20 Date sample collected: - - Hemoglobin x 106/L 22 g/dl g/l mmol/l 23 Date sample collected: Was RBC transfused 30 days before date of test? 25 Platelets 26 x 109/L (x 103/mm3) x 106/L 27 Date sample collected: Were platelets transfused 7 days before date of test? 29 Eosiphils % 31 Date sample collected: - - Basophils 33 % 34 Date sample collected: - - Blasts in blood 36 % 37 Date sample collected: - - Blasts in bone marrow 39 % 40 Date sample collected: - - Were cytogenetics tested (karyotyping or FISH)? 42 Were cytogenetics tested via karyotyping? 43 Date sample collected: Results of tests Abrmalities identified evaluable metaphases abrmalities Specify cytogenetic abrmalities identified at diagsis: 45 % Ph+ metaphases (t(9;22)(q34;q11) and variants) 46 Other abrmality 47 Specify other abrmality: 48 Was documentation submitted to the CIBMTR? 49 Were cytogenetics tested via FISH? 50 Date sample collected: - - Copyright(c) 2012 National Marrow Dor Program and The Medical College of Wisconsin, Inc. All rights reserved. Page 2 / 10
3 Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data 51 Results of tests Abrmalities identified evaluable metaphases abrmalities 52 % Ph+ metaphases (t(9;22)(q34;q11) and variants) 53 Other abrmality 54 Specify other abrmality: 55 Was documentation submitted to the CIBMTR? 56 Were tests for molecular markers performed (e.g. PCR)? 57 Date sample collected: Was BCR / ABL detected? Specify cytogenetic abrmalities identified at diagsis: 59 Specify BCR / ABL breakpoint p190 p210 p230 Other breakpoint 60 Specify other breakpoint: 61 Was BCR / ABL kinase domain mutation analysis performed? 62 T315I 63 WT 64 L248V 65 G250E 66 Q252H 67 Y253F 68 E255K 69 E255V 70 D276G 71 E279K 72 V299L 73 F317L 74 M351T 75 F359V 76 L384M 77 H396P 78 H396R 79 G398R Copyright(c) 2012 National Marrow Dor Program and The Medical College of Wisconsin, Inc. All rights reserved. Page 3 / 10
4 Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data 80 F486S 81 Other mutation 82 Specify other mutation: 83 Was documentation submitted to the CIBMTR? (e.g. pathology report) Pre-HCT or Pre-Infusion Therapy Questions: Was therapy given? Line of Therapy (1) Questions: Systemic therapy 86 Date therapy started Date started: - - Was therapy stopped? 89 Date therapy stopped Date stopped: - - Specify reason therapy stopped 93 Bosutinib (Bosulif) Toxicity t tolerable Lack of response Disease progression Other 92 Specify other reason: 94 Busulfan (Busulfex, Myleran) 95 Corticosteroids 96 Cyclophosphamide (Cytoxan) 97 Cytarabine (Ara-C) 98 Dasatinib (Sprycel) 99 Daurubicin (Cerubidine) 100 Doxorubicin (Adriamycin) 101 Homoharringtonine (HHT) 102 Hydroxyurea (Droxia, Hydrea) 103 Idarubicin (Idamycin) 104 Imatinib (Gleevec) 105 Interferon α (Intron, Roferon) (includes PEG) 106 Methotrexate (MTX) (Amethopterin) 107 Nilotinib (AMN107, Tasigna) 108 Ponatinib (Iclusig) Copyright(c) 2012 National Marrow Dor Program and The Medical College of Wisconsin, Inc. All rights reserved. Page 4 / 10
5 Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data 109 Vincristine (VCR, Oncovin) 110 Other systemic therapy 111 Specify other systemic therapy: 112 Radiation therapy 113 Date therapy started Date started: - - Date therapy stopped 117 Spleen 116 Date stopped: - - Specify site(s) of radiation therapy: 118 Other site(s) 119 Specify other site(s): 120 Splenectomy 121 Other therapy 123 WBC 122 Specify other therapy: Therapy response: 124 x 109/L (x 103/mm3) x 106/L 125 Date sample collected: Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) ted on the WBC differential from the peripheral blood? 127 Basophils 128 % 129 Platelets 130 x 109/L (x 103/mm3) x 106/L 131 Date sample collected: Were platelets transfused 7 days before date of test? 133 Were cytogenetics tested (karyotyping or FISH)? 134 Were cytogenetics tested via karyotyping? 135 Date sample collected: Results of tests Abrmalities identified evaluable metaphases abrmalities Specify cytogenetic abrmalities identified following this line of therapy: 137 % Ph+ metaphases (t(9;22)(q34;q11) and variants) 138 Other abrmality 139 Specify other abrmality: 140 Was documentation submitted to the CIBMTR? Copyright(c) 2012 National Marrow Dor Program and The Medical College of Wisconsin, Inc. All rights reserved. Page 5 / 10
6 Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data 141 Were cytogenetics tested via FISH? 142 Date sample collected: Results of tests Abrmalities identified evaluable metaphases abrmalities 144 % Ph+ metaphases (t(9;22)(q34;q11) and variants) 145 Other abrmality 146 Specify other abrmality: 147 Was documentation submitted to the CIBMTR? 148 Were tests for molecular markers performed (e.g. PCR)? 149 Date sample collected: Was BCR / ABL detected? Specify cytogenetic abrmalities identified following this line of therapy: 151 Specify level of detection 0.1 % > 0.1 % 3 log reduction from standardized baseline < 3-log reduction from standardized baseline 152 Was BCR/ABL level of detection reported on the standardized International Scale (IS)? 153 Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 10 4 ]) 154 Specify BCR / ABL breakpoint p190 p210 p230 Other breakpoint 155 Specify other breakpoint: 156 Was BCR / ABL kinase domain mutation analysis performed? 157 T315I 158 WT 159 L248V 160 G250E 161 Q252H 162 Y253F 163 E255K 164 E255V 165 D276G 166 E279K 167 V299L 168 F317L Copyright(c) 2012 National Marrow Dor Program and The Medical College of Wisconsin, Inc. All rights reserved. Page 6 / 10
7 Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data 169 M351T 170 F359V 171 L384M 172 H396P 173 H396R 174 G398R 175 F486S 176 Other mutation 177 Specify other mutation: 178 Was documentation submitted to the CIBMTR? (e.g. pathology report) 179 Specify the spleen size: centimeters below left lower costal margin 180 Best response to line of therapy Complete hematologic response (CHR) Chronic phase Accelerated phase Blast phase 181 Specify level of best response cytogenetic response ( CyR) Minimal cytogenetic response Mir cytogenetic response Partial cytogenetic response (PCyR) Complete cytogenetic response (CCyR) Major molecular remission (MMR) Complete molecular remission (CMR) 182 Specify blast phase phetype Lymphoid Myeloid Mixed phetype 183 Date assessed: Did disease relapse/progress following this line of therapy? 185 Date of relapse/progression: - - Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: Specify the spleen size: centimeters below left lower costal margin 187 Was extramedullary disease present? Specify site(s) of disease: 188 Central nervous system 189 Granulocytic sarcoma 190 Other site 191 Specify other site: Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) ted on the WBC differential from the peripheral blood? Copyright(c) 2012 National Marrow Dor Program and The Medical College of Wisconsin, Inc. All rights reserved. Page 7 / 10
8 Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data 193 Eosiphils % 195 Date sample collected: - - Basophils 197 % 198 Date sample collected: - - Blasts in blood 200 % 201 Date sample collected: - - Blasts in bone marrow 203 % 204 Date sample collected: - - What was the status of bone marrow fibrosis prior to the preparative regimen / infusion? Absent Mild Moderate Severe 206 Date sample collected: - - Were cytogenetics tested (karyotyping or FISH)? 208 Were cytogenetics tested via karyotyping? 209 Date sample collected: Results of tests Abrmalities identified evaluable metaphases abrmalities Specify cytogenetic abrmalities identified at last evaluation prior to preparative regimen / infusion: 211 % Ph+ metaphases (t(9;22)(q34;q11) and variants) 212 Other abrmality 213 Specify other abrmality: 214 Was documentation submitted to the CIBMTR? 215 Were cytogenetics tested via FISH? 216 Date sample collected: Results of tests Abrmalities identified evaluable metaphases abrmalities 218 % Ph+ metaphases (t(9;22)(q34;q11) and variants) 219 Other abrmality 220 Specify other abrmality: 221 Was documentation submitted to the CIBMTR? 222 Were tests for molecular markers performed (e.g. PCR)? 223 Date sample collected: Was BCR / ABL detected? Specify cytogenetic abrmalities identified at last evaluation prior to preparative regimen / infusion: 225 Specify level of detection 0.1 % > 0.1 % 3 log reduction from standardized baseline < 3-log reduction from standardized baseline Copyright(c) 2012 National Marrow Dor Program and The Medical College of Wisconsin, Inc. All rights reserved. Page 8 / 10
9 Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data 226 Was BCR/ABL level of detection reported on the standardized International Scale (IS)? 227 Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 10 4 ]) 228 Specify BCR / ABL breakpoint p190 p210 p230 Other breakpoint 229 Specify other breakpoint: 230 Was BCR / ABL kinase domain mutation analysis performed? 231 T315I 232 WT 233 L248V 234 G250E 235 Q252H 236 Y253F 237 E255K 238 E255V 239 D276G 240 E279K 241 V299L 242 F317L 243 M351T 244 F359V 245 L384M 246 H396P 247 H396R 248 G398R 249 F486S 250 Other mutation 251 Specify other mutation: 252 Was documentation submitted to the CIBMTR? (e.g. pathology report) Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: Copyright(c) 2012 National Marrow Dor Program and The Medical College of Wisconsin, Inc. All rights reserved. Page 9 / 10
10 Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data 253 What was the disease status? Complete hematologic response (CHR) Chronic phase Accelerated phase Blast phase 254 Specify level of response cytogenetic response ( CyR) Minimal cytogenetic response Mir cytogenetic response Partial cytogenetic response (PCyR) Complete cytogenetic response (CCyR) Major molecular remission (MMR) Complete molecular remission (CMR) 255 Specify blast phase phetype Lymphoid Myeloid Mixed phetype 256 Date assessed: - - First Name: Last Name: address: Date: - - Copyright(c) 2012 National Marrow Dor Program and The Medical College of Wisconsin, Inc. All rights reserved. Page 10 / 10
CIBMTR Center Number: CIBMTR Recipient ID: Today s Date: Date of HSCT for which this form is being completed:
Chronic Myelogenous Leukemia (CML) Post-HSCT Data Sequence Number: Date Received: Registry Use Only Today s Date: Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic,
More informationForm 2011 R4.0: Acute Lymphoblastic Leukemia (ALL) Pre-HCT Data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Date of HCT for which this form is being completed: - - HCT type: (check all that apply) Autologous Allogeneic,
More informationscreening procedures Disease resistant to full-dose imatinib ( 600 mg/day) or intolerant to any dose of imatinib
Table S1. Study inclusion and exclusion criteria Inclusion criteria Aged 18 years Signed and dated informed consent form prior to protocol-specific screening procedures Cytogenetic- or PCR-based diagnosis
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationCML: definition. CML epidemiology. CML diagnosis. CML: peripheralbloodsmear. Cytogenetic abnormality of CML
MolecularDiagnostic.be Third Scientific Meeting Molecular Diagnostics.be t(9;22) CML: definition Management of CML patients treated with TKI: the place of molecular monitoring Antwerp, December 13 th 11
More informationCML TREATMENT GUIDELINES
CML TREATMENT GUIDELINES INITIAL INVESTIGATION Propose enrolment in the CML Registry of the CML-MPN Quebec Research Group. Medical history : Question for cardio-respiratory disorders, diabetes, pancreatitis,
More informationA 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.
1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)
More informationCML and Future Perspective. Hani Al-Hashmi, MD
CML and Future Perspective Hani Al-Hashmi, MD Objectives Learning from CML history Outcome of interest to clinician Patient and community interest!! Learning from CML history Survival Probability (All
More informationThe speaker has no financial relationships with a commercial interest to disclose and no conflicts of interest to resolve.
Hana Safah MD Professor of Medicine Tulane University School of Medicine Director of the SCT program, Tulane Medical Center The speaker has no financial relationships with a commercial interest to disclose
More informationICLUSIG (ponatinib) oral tablet
ICLUSIG (ponatinib) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationMolecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML
Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML Imran Mirza, MD, MS, FRCPC Pathology & Laboratory Medicine Institute Sheikh Khalifa Medical City, Abu Dhabi, UAE. imirza@skmc.ae
More informationCML Clinical Case Scenario
CML Clinical Case Scenario Neil Shah, MD, PhD Edward S. Ageno Distinguished Professor in Hematology/Oncology Leader, Hematopoietic Malignancies Program Helen Diller Family Comprehensive Cancer Center at
More informationMP BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia
Medical Policy BCBSA Ref. Policy: 2.04.85 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 8.01.30 Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia
More informationBOSULIF (bosutinib) oral tablet
BOSULIF (bosutinib) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationA COMPARATIVE EFFECTIVENESS ANALYSIS OF PATIENTS NEWLY INITIATING TYROSINE KINASE INHIBITOR THERAPY FOR CHRONIC MYELOID LEUKEMIA.
A COMPARATIVE EFFECTIVENESS ANALYSIS OF PATIENTS NEWLY INITIATING TYROSINE KINASE INHIBITOR THERAPY FOR CHRONIC MYELOID LEUKEMIA Melea Ward A dissertation submitted to the faculty of the University of
More informationChronic Myeloid Leukaemia Guidelines
Chronic Myeloid Leukaemia Guidelines Approved by Pathway Board for Haematological Malignancies Coordinating author: Heather Oakervee, Bart s Health NHST Date of issue: 12.03.2015 Version number:v1.0 These
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 March 2007 SPRYCEL 20 mg, film-coated tablet, blister (377 637-9) SPRYCEL 20 mg, film-coated tablet, bottle (377
More informationSESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
SESSION III: Chronic myeloid leukemia PONATINIB Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Ponatinib A Pan-BCR-ABL Inhibitor Rationally designed inhibitor of BCR- ABL
More informationBosulif. Bosulif (bosutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review
More informationMyeloproliferative Neoplasms
Myeloproliferative Neoplasms Judit Demeter CML chronic myeloid leukemia Semmelweis University, I st Department of Internal Medicine PV polycythaemia vera ET essential thrombocythaemia MF myelofibrosis
More informationChronic Myeloid Leukemia
Chronic Myeloid Leukemia Paula, CML survivor This publication was supported by Revised 2014 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma
More informationCML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML
1 CML 2012 LLS Jan 26, 2012 David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML 2012 Current treatment options for CML patients Emerging therapies for CML treatment
More informationRole of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML. GIUSEPPE SAGLIO, MD University of Torino, Italy
Role of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML GIUSEPPE SAGLIO, MD University of Torino, Italy Outcome in 282 Patients Treated with Imatinib First Line in Hammersmith Hospital
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationStopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase
More informationChronic myeloid leukemia (CML) Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University
Chronic myeloid leukemia (CML) 1 Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University Hematologic malignancies CML ALL AML 2 CML CD34+ results from an acquired mutation that affects hematopoietic
More informationVenice Meeting Highlights: Key lessons. Conclusions Michele Baccarani Rüdiger Hehlmann
Venice Meeting Highlights: Key lessons Conclusions Michele Baccarani Rüdiger Hehlmann CML therapy in the imatinib era CML prognosis has improved dramatically Cellular and molecular biology studies help
More informationCML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES. by Sarunas Narbutas Jan Geissler.
CML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES by Sarunas Narbutas Jan Geissler 4 May 2018 CML 101 / BASICS: UNDERSTANDING THE DISCUSSIONS IN CML SESSIONS What
More informationWhat Can We Expect from Imatinib? CML Case Presentation. Presenter Disclosure Information. CML Case Presentation (cont)? Session 2: 8:15 AM - 9:00 AM
Welcome to Master Class for Oncologists Session 2: 8:15 AM - 9: AM Miami, FL December 18, 29 Chronic Myelocytic Leukemia: Imatinib and Beyond Speaker: Daniel J. DeAngelo, MD, PhD Dana-Farber Cancer Institute
More informationHematologic and cytogenetic responses of Imatinib Mesylate and significance of Sokal score in chronic myeloid leukemia patients
ORIGINAL ALBANIAN MEDICAL RESEARCH JOURNAL Hematologic and cytogenetic responses of Imatinib Mesylate and significance of Sokal score in chronic myeloid leukemia patients Dorina Roko 1, Anila Babameto-Laku
More informationt(9;22)(q34;q11) as part of a single or complex translocation, or BCR-ABL transcripts must be present in every case
CHRONIC MYELOID LEUKAEMIA Diagnostic Criteria Chronic phase CML t(9;22)(q34;q11) as part of a single or complex translocation, or BCR-ABL transcripts must be present in every case Maximally cellular marrow
More informationCurrent Monitoring for CML: Goals and. Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center
Current Monitoring for CML: Goals and Principles Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center Survival in Early Chronic Phase CML MDACC 2009 The Philadelphia
More informationChronic Myeloid Leukemia
NCCN GUIDELINES FOR PATIENTS 2018 Please complete our online survey at NCCN.org/patients/survey Chronic Myeloid Leukemia Presented with support from: Available online at NCCN.org/patients Ü Chronic Myeloid
More informationJuvenile Myelomonocytic Leukemia Pre-HCT Data
Instructions for Juvenile Myelomonocytic Leukemia Pre-HCT Data (Form 2015) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the JMML Pre-HCT Form. E-mail
More informationCancer Biology 2016;6(1) Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia patients in Upper Egypt. Mervat M.
Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia patients in Upper Egypt Mervat M. Omar Department of Oncology, Assuit University Hospital, Assuit, Egypt drmervatomar@yahoo.com Abstract: Background
More informationManagement of CML in blast crisis. Lymphoma Tumor Board November 27, 2015
Management of CML in blast crisis Lymphoma Tumor Board November 27, 2015 Chronic Phase CML - 2. Peter Maslak, ASH Image Bank 2011; 2011-2455 Copyright 2011 American Society of Hematology. Copyright restrictions
More informationState of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds Hackensack, New Jersey. September 22, 2010
State of the Art Therapy and Monitoring of CML - 2010 Hagop Kantarjian, M.D. Grand Rounds Hackensack, ew Jersey September 22, 2010 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course
More informationDiagnosis and Management of Chronic Myeloid Leukaemia
Diagnosis and Management of Chronic Myeloid Leukaemia Dr Simon Watt Dr Katherine O Neill Dr Fiona Dignan Written July 2017 Prof Tim Somervaille Review July 2019 1 Table of Contents 1.0 Introduction 3 2.0
More informationThe CML Guide. Information for Patients and Caregivers. Chronic Myeloid Leukemia. Matthew, CML survivor. This publication was supported by
The CML Guide Information for Patients and Caregivers Chronic Myeloid Leukemia Matthew, CML survivor This publication was supported by Revised 2017 Booklet Updates The Leukemia & Lymphoma Society wants
More informationDiscontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: What s Stopping us from Stopping?
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: What s Stopping us from Stopping? David Pham, PharmD PGY2 Hematology/Oncology Pharmacy Resident South Texas VA Health Care System
More informationSubject: Dasatinib (Sprycel ) Tablets
09-J1000-43 Original Effective Date: 01/01/12 Reviewed: 01/10/18 Revised: 02/15/18 Subject: Dasatinib (Sprycel ) Tablets THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationC Longer follow up on IRIS data
hronic Myeloid Leukemia Drs. Rena Buckstein, Mervat Mahrous & Eugenia Piliotis with input from Dr. J. Lipton (PMH) Updated August 2008* Updates: C Longer follow up on IRIS data Guidelines for monitoring
More informationDETERMINANT VALUE OF THE CYTOGENETIC AND MOLECULAR IMATINIB THERAPEUTIC RESPONSE IN CHRONIC MYELOID LEUKEMIA
Analele Ştiinţifice ale Universităţii Alexandru Ioan Cuza, Secţiunea Genetică şi Biologie Moleculară, TOM XIV, 2013 DETERMINANT VALUE OF THE CYTOGENETIC AND MOLECULAR IMATINIB THERAPEUTIC RESPONSE IN CHRONIC
More informationHodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data
Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: CIBMTR Research ID: Event date: / / Visit 100 day 6 months 1 year 2 years
More informationAbstract. Research. Keywords: CML, Sokal score, Euro score, EUTOS score. Published: 06/10/2016 Received: 29/05/2016
Prognostic and predictive implications of Sokal, Euro and eutos scores in chronic myeloid leukaemia in the imatinib era experience from a tertiary oncology centre in Southern India Lakshmaiah Chinnagiriyappa
More informationCML HORIZONS 101 AND CML 101
CML HORIZONS 101 AND CML 101 by Pat Garcia-Gonzalez, USA May 1, 2015 Barcelona, Spain Goals of this Session Everything you ever wanted to know and were afraid of asking Help you navigate the conference
More informationBlast Phase Chronic Myelogenous Leukemia
Blast Phase Chronic Myelogenous Leukemia Benjamin Powers, MD; and Suman Kambhampati, MD The dramatic improvement in survival with tyrosine kinase inhibitors has not been demonstrated in the advanced blast
More informationCML CML CML. tyrosine kinase inhibitor CML. 22 t(9;22)(q34;q11) chronic myeloid leukemia CML ABL. BCR-ABL c- imatinib mesylate CML CML BCR-ABL
1 Key Wordschronic myeloid leukemiaimatinib mesylate tyrosine kinase inhibitor chronic myeloid leukemia CML imatinib mesylate CML CML CML CML Ph 10 1 30 50 3 5 CML α IFNα Ph Ph cytogenetic response CRmajor
More informationContemporary and Future Approaches in CML. Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D.
Contemporary and Future Approaches in CML Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D. 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis
More informationELN Recommendations on treatment choice and response. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
ELN Recommendations on treatment choice and response Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy ELN 2013 Response to Front-line Treatment Baseline 3 months 6 months OPTIMAL
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationHEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA
LEUKEMIA Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent
More informationIS MUTATION ANALYSIS OF BCR-ABL OF ANY VALUE IN CLINICAL MANAGEMENT OF CML PATIENTS? David Marin, Imperial College London
IS MUTATION ANALYSIS OF BCR-ABL OF ANY VALUE IN CLINICAL MANAGEMENT OF CML PATIENTS? David Marin, Imperial College London Tell me generals, are we politicians necessary? I have to admit defeat before starting
More informationChronic Myeloid Leukemia A Disease of Young at Heart but Not of Body
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,
More informationSede Amministrativa: Università degli Studi di Padova
Sede Amministrativa: Università degli Studi di Padova Dipartimento di Scienze del Farmaco CORSO DI DOTTORATO DI RICERCA IN SCIENZE FARMACOLOGICHE CURRICOLO: FARMACOLOGIA, TOSSICOLOGIA E TERAPIA XXX CICLO
More informationClinical Guidelines for Leukaemia and other Myeloid Disorders Myeloproliferative Neoplasms
Clinical Guidelines for Leukaemia and other Myeloid Disorders Myeloproliferative Neoplasms Reference Number Version Status Executive Lead(s) Name and Job Title Author(s) Name and Job Title 13-2H-106 1
More informationCHRONIC MYELOID LEUKEMIA. Dr.M SAI SRAVANTHI POST GRADUATE DEPT OF GENERAL MEDICINE KAMINENI INSTITUTE OF MEDICAL SCIENCES
CHRONIC MYELOID LEUKEMIA Dr.M SAI SRAVANTHI POST GRADUATE DEPT OF GENERAL MEDICINE KAMINENI INSTITUTE OF MEDICAL SCIENCES CHRONIC MYELOID LEUKEMIA INCIDENCE The incidence of CML is 1.5 per 100,000 people
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1of 5 Last Review Date: September 15, 2017 Tasigna Description Tasigna (nilotinib)
More informationChronic Myeloid Leukaemia
Chronic Myeloid Leukaemia Molecular Response: What is really important? Jeff Szer The Royal Melbourne Hospital PROBABILITY, % PROBABILITY OF SURVIVAL AFTER MYELOABLATIVE TRANSPLANTS FOR CML IN CHRONIC
More informationIRIS 8-Year Update. Management of TKI Resistance Will KD mutations matter? Sustained CCyR on study. 37% Unacceptable Outcome 17% 53% 15%
Management of TKI Resistance Will KD mutations matter? IRIS 8-Year Update 17% 53% 5% 15% 37% Unacceptable Outcome No CCyR Lost CCyR CCyR Other 3% 7% Safety Lost-regained CCyR Sustained CCyR on study Deininger
More informationNew drugs and trials. Andreas Hochhaus
New drugs and trials. Andreas Hochhaus Hadera I Oct 2018 Introduction ABL001 is a potent, specific inhibitor of BCR-ABL1 with a distinct allosteric mechanism of action BCR-ABL1 Protein Binds a distinct
More informationCML Glossary (and abbreviations) INTRODUCTION: Glossary and abbreviations. Richard Rockefeller, MD. Updated in 2015 by the CML Society of Canada.
CML Glossary (and abbreviations) Richard Rockefeller, MD. Updated in 2015 by the CML Society of Canada. INTRODUCTION: Included here are terms specifically related to the disease of CML, as well as some
More informationTRANSPARENCY COMMITTEE OPINION. 14 February 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 February 2007 GLIVEC 100 mg, capsule B/120 capsules (CIP: 358 493-5) GLIVEC 100 mg, capsule B/180 capsules (CIP:
More information2 nd Generation TKI Frontline Therapy in CML
2 nd Generation TKI Frontline Therapy in CML Elias Jabbour, M.D. April 212 New York Frontline Therapy of CML in 212 - imatinib 4 mg daily - nilotinib 3 mg BID - dasatinib 1 mg daily Second / third line
More information10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD Dalia Khan 1, Noemi Roy 1, Vasha Bari 1, Grant Vallance 1, Helene Dreau 1, Timothy Littlewood 1, Andrew Peniket 1, Paresh Vyas
More informationMRD in CML (BCR-ABL1)
MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:
More informationDAVID S. SNYDER, M.D.
CML UPDATE 2019 DAVID S. SNYDER, M.D. MARCH 21,2019 Click to edit Master Presentation Date Disclosures I do not have anything to disclose 2001 2016 Loss in expectation of life of patients with chronic
More informationPeripheral Blood Monitoring of Chronic Myeloid Leukemia During Treatment With Imatinib, Second-Line Agents, and Beyond
Peripheral Blood Monitoring of Chronic Myeloid Leukemia During Treatment With Imatinib, Second-Line Agents, and Beyond Lisa Lima, MS 1 ; Leon Bernal-Mizrachi, MD 1 ; Debra Saxe, PhD 2 ; Karen P. Mann,
More informationClinical Significance of ABL Kinase Domain Mutation in Chronic Myeloid Leukemia under Imatinib Therapy.
Clinical Significance of ABL Kinase Domain Mutation in Chronic Myeloid Leukemia under Imatinib Therapy 1 Amr A.Ghannam, Abdou S. M. 2 and Mona Hatata 2 1 Department of Clinical Oncology, Tanta university
More informationAcute Lymphoblastic and Myeloid Leukemia
Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women
More informationHistory of CML Treatment
History of CML Treatment Eduardo Olavarria No conflict of interest Lisbon, 20th March 2018 #EBMT18 www.ebmt.or What is CML? The mystery of chronic myeloid leukaemia Chronic myeloid leukaemia Often diagnosed
More informationState of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds UT Southwestern. October 28, 2010
State of the Art Therapy and Monitoring of CML - 2010 Hagop Kantarjian, M.D. Grand Rounds UT Southwestern October 28, 2010 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal
More informationTaiwan Guidelines for the Management of Chronic Myeloid Leukemia
Taiwan Guidelines for the Management of Chronic Myeloid Leukemia Taiwan CML Study Group Coordinator: Lee-Yung Shih 2013/11/30 1 Contents Initial work-up at diagnosis and define baseline prognostic factors
More informationContemporary and Future Approaches in Management of CML. Disclosures
Winship Cancer Institute of Emory University Contemporary and Future Approaches in Management of CML Hagop Kantarjian, MD Chairman and Professor, Department of Leukemia University of Texas M. D. Anderson
More informationIn this issue of the journal two articles deal with different
EDITORIALS & PERSPECTIVES Monitoring treatment of chronic myeloid leukemia Michele Baccarani, 1 Fabrizio Pane, 2 and Giuseppe Saglio 3 1 Department of Hematology-Oncology "L. and A. Seràgnoli" University
More informationJeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ
Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ What is acute leukemia? Cancer of the white blood cells Acute leukemia- Acute myelogenous leukemia Acute myeloid leukemia Myelofibrosis- Blast phase
More informationChronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
Received: 13 December 2017 Accepted: 17 December 2017 DOI: 10.1002/ajh.25011 ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
More informationTreatment and Survival in Patients with Chronic Myeloid Leukemia in a Chronic Phase in the West of Iran
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.17.7555 RESEARCH ARTICLE Treatment and Survival in Patients with Chronic Myeloid Leukemia in a Chronic Phase in the West of Iran Mehrdad Payandeh 1&, Masoud
More informationChronic Myeloid Leukemia
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2018 July 26, 2017 NCCN.org Continue Version 1.2018, 07/26/17 National Comprehensive Cancer Network, Inc. 2017, All rights reserved.
More informationHSCT for Myeloproliferative Disorders. Jane Apperley
HSCT for Myeloproliferative Disorders Jane Apperley Myeloproliferative disorders CML Polycythemia vera Essential thrombocythemia Primary myelofibrosis bcr-abl + bcr-abl - JAK2 (valine to phenylalanin an
More informationSummary 1. Comparative effectiveness of ponatinib
Cost-effectiveness of ponatinib (Iclusig ) as indicated for adult patients with: (i) CP-, AP-, or BP- chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationWhat is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR
What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR after 18 months of imatinib? Second generation TKIs as a bridge to allogeneic SCT
More informationIntroduction to Cancer
Introduction to Cancer Clonal Evolution Theory of Tumor Development,2,2,,2,2,,2, Numbers represent sequential mutations to cellular genes Oncogenes and Tumor Suppresser Genes On Oncogenes Tumor Suppresser
More informationWhat is New in CML in Hagop Kantarjian, M.D. February 2011
What is New in CML in 2011 Hagop Kantarjian, M.D. February 2011 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis Poor Excellent 10-yr survival 10% 84-90%
More informationShould nilotinib replace imatinib as first line treatment of chronic myeloid leukemia in chronic phase (CML-CP)?
Should nilotinib replace imatinib as first line treatment of chronic myeloid leukemia in chronic phase (CML-CP)? http://test.metromomsblog.org/wp-content/uploads/2010/02/tortoise-and-the-hare.jpg D. Van
More informationChronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
clinical practice guidelines Annals of Oncology 23 (Supplement 7): vii72 vii77, 2012 doi:10.1093/annonc/mds228 Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
More informationHematopathology Case Study
Hematopathology Case Study AMP Outreach Course 2009 AMP Annual Meeting John Greg Howe Ph.D. Department of Laboratory Medicine Yale University School of Medicine November 19, 2009 HISTORY Case History An
More informationHull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway. Chronic Myeloid Leukaemia
Hull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway Chronic Myeloid Leukaemia 1 BACKGROUND The Hull and North Lincolnshire Haematology Multidisciplinary
More informationHematologic Malignancies. Eunice S. Wang MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine
Hematologic Malignancies Eunice S. Wang MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine Blood cancers are normal blood cells gone bad Jordan C et
More informationExtramedullary precursor T-lymphoblastic transformation of CML at presentation
Extramedullary precursor T-lymphoblastic transformation of CML at presentation Neerja Vajpayee, Constance Stein, Bernard Poeisz & Robert E. Hutchison Clinical History 30 year old man presented to the emergency
More informationHow I treat high risck CML
Torino, September 14, 2018 How I treat high risck CML Patrizia Pregno Hematology Dept. Citta della Salute e della Scienza Torino Disclosures Advisory Board: Novartis, Pfizer, Incyte Speaker Honoraria:
More informationGreater Manchester and Cheshire Cancer Network Chronic Myeloid Leukaemia v3 2012
Greater Manchester and Cheshire Cancer Network Chronic Myeloid Leukaemia v3 2012 Dr Simon Watt Dr Shiva Natarajan 1.0 Introduction The landscape in chronic myeloid leukaemia (CML) has changed dramatically
More informationOutlook CML 2016: What is being done on the way to cure
New Horizons 2011 Outlook CML 2016: What is being done on the way to cure Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA CML Working Party
More informationBMS Satellite Symposium
ICKSH 2018 BMS Satellite Symposium Emerging Trends in CML Management CHAIRMAN The Head of Catholic Hematology Hospital The Director of the Catholic Leukemia Research Institute at the Catholic University
More informationForm 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Has this patient's data been previously reported to USIDNET? USIDNET ID: Today's Date: - - Date of HSCT for which
More informationGuidelines and real World: Management of CML in chronic and advanced phases. Carolina Pavlovsky. FUNDALEU May 2017 Frankfurt
Guidelines and real World: Management of CML in chronic and advanced phases Carolina Pavlovsky. FUNDALEU 26-28 May 217 Frankfurt Some Issues in CML 217 First Line treatment: Imatinib vs 2nd generation
More informationChronic Myeloid Leukemia
Chronic Myeloid Leukemia Paula, CML survivor Support for this publication provided by Revised 2017 Booklet Updates The Leukemia & Lymphoma Society wants you to have the most up-to-date information about
More information